HBIO Quote, Financials, Valuation and Earnings

Azenta, Inc. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -3.49%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Azenta, Inc.'s return on equity of 1.7%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 225.89%. On the other hand Azenta, Inc. has an analysts' consensus of $38.67 which suggests that it could grow by 43.32%. Given that Harvard Bioscience, Inc. has higher upside potential than Azenta, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Azenta, Inc..

Harvard Bioscience, Inc. has a beta of 1.548, which suggesting that the stock is 54.788% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.349, suggesting its more volatile than the S&P 500 by 34.927%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are smaller than Azenta, Inc. quarterly revenues of $148.6M. Harvard Bioscience, Inc.'s net income of -$1.2M is higher than Azenta, Inc.'s net income of -$5.2M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.31x versus 2.08x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories, Inc. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -52.36%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Bio-Rad Laboratories, Inc.'s return on equity of 10.99%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 225.89%. On the other hand Bio-Rad Laboratories, Inc. has an analysts' consensus of $324.00 which suggests that it could grow by 16.36%. Given that Harvard Bioscience, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Harvard Bioscience, Inc. has a beta of 1.548, which suggesting that the stock is 54.788% more volatile than S&P 500. In comparison Bio-Rad Laboratories, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 18.018%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bio-Rad Laboratories, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Bio-Rad Laboratories, Inc. pays out -- of its earnings as a dividend.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are smaller than Bio-Rad Laboratories, Inc. quarterly revenues of $693.2M. Harvard Bioscience, Inc.'s net income of -$1.2M is lower than Bio-Rad Laboratories, Inc.'s net income of $720M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Bio-Rad Laboratories, Inc.'s PE ratio is 9.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.31x versus 2.94x for Bio-Rad Laboratories, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics, Inc. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of -115.42%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Bionano Genomics, Inc.'s return on equity of -84.77%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 225.89%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $7.50 which suggests that it could grow by 552.17%. Given that Bionano Genomics, Inc. has higher upside potential than Harvard Bioscience, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Harvard Bioscience, Inc..

Harvard Bioscience, Inc. has a beta of 1.548, which suggesting that the stock is 54.788% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.683, suggesting its more volatile than the S&P 500 by 68.319%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are larger than Bionano Genomics, Inc. quarterly revenues of $7.4M. Harvard Bioscience, Inc.'s net income of -$1.2M is higher than Bionano Genomics, Inc.'s net income of -$8.5M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.31x versus 0.13x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -5.98% compared to Harvard Bioscience, Inc.'s net margin of 2.99%. Harvard Bioscience, Inc.'s return on equity of -155.33% beat Bruker Corp.'s return on equity of -0.39%.

Harvard Bioscience, Inc. has a consensus price target of $2.00, signalling upside risk potential of 225.89%. On the other hand Bruker Corp. has an analysts' consensus of $48.43 which suggests that it could grow by 20.74%. Given that Harvard Bioscience, Inc. has higher upside potential than Bruker Corp., analysts believe Harvard Bioscience, Inc. is more attractive than Bruker Corp..

Harvard Bioscience, Inc. has a beta of 1.548, which suggesting that the stock is 54.788% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.621%.

Harvard Bioscience, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.5% to investors and pays a quarterly dividend of $0.05 per share. Harvard Bioscience, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Harvard Bioscience, Inc. quarterly revenues are $20.6M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Harvard Bioscience, Inc.'s net income of -$1.2M is lower than Bruker Corp.'s net income of $29.2M. Notably, Harvard Bioscience, Inc.'s price-to-earnings ratio is -- while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Harvard Bioscience, Inc. is 0.31x versus 1.77x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.